The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ANAB | +265.36% | +211.91% | +25.55% | +251% |
| S&P | +17.78% | +74.31% | +11.75% | +196% |
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
This biotech innovator in antibody therapies just reported a significant insider sale amid a period of strong share price gains.
This clinical-stage biotech specializing in antibody therapeutics reported a notable insider sale amid ongoing development and partnerships.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $108.25M | 151.1% |
| Gross Profit | $107.64M | 153.2% |
| Gross Margin | 99.44% | 0.8% |
| Market Cap | $1.34B | 233.2% |
| Market Cap / Employee | $12.91M | 0.0% |
| Employees | 104 | -23.5% |
| Net Income | $49.61M | 327.8% |
| EBITDA | $67.51M | 844.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $238.20M | 93.5% |
| Accounts Receivable | $33.85M | -17.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $288.56M | -21.5% |
| Short Term Debt | $2.08M | 8.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -3.12% | 27.9% |
| Return On Invested Capital | -23.00% | -1.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $98.00M | 246.2% |
| Operating Free Cash Flow | $98.00M | 246.8% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.99 | 19.83 | -19.15 | -45.45 | -1051.69% |
| Price to Sales | 5.09 | 5.19 | 5.24 | 6.48 | 46.66% |
| Price to Tangible Book Value | 7.99 | 19.83 | -19.15 | -45.45 | -1051.69% |
| Price to Free Cash Flow TTM | 77.49 | - | |||
| Enterprise Value to EBITDA | -21.38 | -28.17 | 27.92 | 22.20 | -151.99% |
| Free Cash Flow Yield | 1.3% | - | |||
| Return on Equity | -182.7% | -343.8% | -308.0% | -24.5% | -84.87% |
| Total Debt | $345.96M | $346.46M | $346.45M | $290.64M | -21.33% |
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
